ArticleJournal of inflammation research2026
Beyond Single Biomarkers: A Multidimensional Risk Score for Improved Post-Transplant Prognosis Prediction in Hepatocellular Carcinoma.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inflammation- and nutrition-related biomarkers are associated with prognosis in hepatocellular carcinoma (HCC), but most studies have focused on single markers. This study aimed to develop and internally validate a multidimensional inflammatory-nutritional risk score (RS) for predicting post-transplant outcomes in HCC patients. Materials and methods: This single-center retrospective cohort included 239 patients with pathologically confirmed HCC who underwent liver transplantation between April 2013 and July 2023. Fourteen preoperative inflammation- and nutrition-related markers were calculated from laboratory data obtained within one week before transplantation. A bootstrap LASSO-Cox framework with 2000 resampling iterations was used to identify stable prognostic markers, and those selected in >70% of iterations were retained for the primary RS. Overall survival (OS) and recurrence-free survival (RFS) were assessed. Model performance was evaluated using Cox regression, C-index, time-dependent ROC analysis, calibration, decision curve analysis, and bootstrap optimism-corrected internal validation. Results: During a median follow-up of 53 months, 83 OS events and 89 RFS events occurred. Four markers, including fibrinogen-to-albumin ratio, gamma-glutamyl transpeptidase-to-prealbumin ratio, gamma-glutamyl transpeptidase-to-albumin ratio, and aspartate aminotransferase-to-neutrophil ratio index, were selected to construct the primary RS. Patients with high RS had significantly worse OS and RFS than those with low RS, and RS remained independently associated with both outcomes in multivariable Cox analyses. Adding RS improved prognostic performance beyond Milan criteria, Hangzhou criteria, UCSF criteria, and clinicopathological models incorporating alpha-fetoprotein, tumor burden, portal vein tumor thrombus, and microvascular invasion. The final RS-plus clinicopathological model achieved apparent C-indices of 0.766 for OS and 0.759 for RFS, with bootstrap optimism-corrected C-indices of 0.756 and 0.749, respectively. Conclusion: A four-marker inflammatory-nutritional RS based on routinely available preoperative biomarkers was independently associated with OS and RFS after liver transplantation for HCC and provided incremental prognostic information beyond established criteria and clinicopathological factors. Because the RS-plus model incorporates microvascular invasion, it should be interpreted as a postoperative prognostic tool. External validation is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.